natgillin/translations-raw huggingface dataset:
Forsøg 0046 var et internationalt, multicenter, open-label, eksploratorisk forsøg med Arimidex hos 28 piger (i alderen 2 til ≤ 10 år) med McCune-Albright syndrom (MAS). 
Trial 0046 was an international, multi-centre, open-label exploratory trial of Arimidex in 28 girls (aged 2 to ≤ 10 years) with McCune-Albright Syndrome (MAS).
Arimidex fungerer ved at nedsætte mængden af hormonet østrogen, som din krop producerer. 
Arimidex works by cutting down the amount of the hormone called estrogen that your body makes.
• Betændelse i leddene (artrit). 
• Inflammation of the joints (arthritis).
I akutte toksicitetsforsøg med gnavere var den gennemsnitlige letale dosis af anastrozol større end 100 mg/kg/dag oralt og større end 50 mg/kg/dag intraperitonealt. 
In acute toxicity studies in rodents, the median lethal dose of anastrozole was greater than 100 mg/kg/day by the oral route and greater than 50 mg/kg/day by the intraperitoneal route.
I et fase III/IV-studie (Study of Anastrozole with the Bisphosphonate Risedronate [SABRE]) blev 234 postmenopausale kvinder med hormonreceptor-positiv tidlig brystkræft, planlagt til behandling med Arimidex 1 mg/dag, stratificeret til lav, moderat og høj risikogruppe i henhold til deres eksisterende risiko for fraktur på grund af øget knogleskørhed. 
In the phase III/IV study (Study of Anastrozole with the Bisphosphonate Risedronate [SABRE]), 234 postmenopausal women with hormone receptor-positive early breast cancer scheduled for treatment with Arimidex 1 mg/day were stratified to low, moderate and high risk groups according to their existing risk of fragility fracture.
Tid til fjernt recidiv defineres som den første forekomst af fjernt recidiv eller død på grund af brystkræft. 
Time to distant recurrence is defined as the first occurrence of distant recurrence or death due to breast cancer.
I alt 764 patienter blev randomiseret til at få enten 1 mg eller 10 mg Arimidex en gang dagligt eller megestrolacetat 40 mg fire gange dagligt. 
A total of 764 patients were randomised to receive either a single daily dose of 1 mg or 10 mg of Arimidex or megestrol acetate 40 mg four times a day.
Hvis du har glemt at tage Arimidex 
If you forget to take Arimidex
Oral indgift af anastrozol til hunrotter gav en høj forekomst af infertilitet ved 1 mg/kg/dag og øgede præimplantationstabet ved 0,02 mg/kg/dag. 
Oral administration of anastrozole to female rats produced a high incidence of infertility at 1 mg/kg/day and increased pre-implantation loss at 0.02 mg/kg/day.
I dyreforsøg forekom der kun bivirkninger ved høje doser. 
In animal studies adverse effects were only seen at high doses.
Der blev ikke observeret nogen klinisk signifikante ændringer i Tanner-stadieinddeling, middel ovarievolumen eller middel uterusvolumen. 
There were no clinically significant changes in Tanner staging, mean ovarian volume, or mean uterine volume.
Arimidex udviser ikke nogen gestagen, androgen eller østrogen aktivitet. 
Arimidex does not possess any progestogenic, androgenic, or estrogenic activity.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukken tablet indeholder 1 mg anastrozol. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 1 mg anastrozole.
Arimidexdoser på op til 10 mg dagligt har ingen indvirkning på udskillelsen af cortisol eller aldosteron, målt før eller efter standard ACTH-test. Der er derfor ikke behov for kortikoid-tilskud. 
Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard adrenocorticotrophic hormone (ACTH) challenge testing.
Tag altid Arimidex nøjagtigt efter lægens anvisning. 
Always take Arimidex exactly as your doctor has told you.
Arimidex bør ikke anvendes til børn og unge på grund af utilstrækkelige data vedrørende sikkerhed og virkning (se pkt. 
Arimidex is not recommended for use in children and adolescents due to insufficient data on safety and efficacy (see sections 4.4 and 5.1).
Forsøg 0001 var et open-label, farmakokinetisk studie med Arimidex 1 mg/dag hos 36 drenge i puberteten med gynækomasti af mindre end 12 måneders varighed. 
Trial 0001 was an open-label, multiple-dose pharmacokinetic study of Arimidex 1 mg/day in 36 pubertal boys with gynaecomastia of less than 12 months duration.
12-måneders hovedanalyse viste, at patienter med eksisterende moderat til høj risiko for fraktur ikke havde et fald i knogledensitet (vurderet ud fra knogledensitet i columna lumbalis ved hjælp af DXAscanning), når de blev behandlet med Arimidex 1 mg/dag i kombination med risedronat 35 mg en gang om ugen. 
The 12-month main analysis has shown that patients already at moderate to high risk of fragility fracture showed no decrease in their bone mass density (assessed by lumbar spine bone mineral density using DEXA scanning) when managed by using Arimidex 1 mg/day in combination with risedronate 35 mg once a week.
Sygdomsfri overlevelse inkluderer alle recidiverende hændelser og defineres som den første forekomst af loko-regionalt recidiv, kontralateral ny brystkræft, fjernt recidiv eller død (uanset årsag). 
Disease-free survival includes all recurrence events and is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death (for any reason).
Hårudtynding (alopeci) Allergiske reaktioner Ikke almindelig Urticaria Sjælden 
Hair thinning (alopecia) Allergic reactions
Studie 1033IL/0027 viste, at objektive tumorresponsrater og tid til tumorprogression var sammenlignelige for Arimidex og tamoxifen. 
Study 1033IL/0027 showed that Arimidex and tamoxifen had similar objective tumour response rates and time to tumour progression.
I et open-label, ikke-komparativt, multicenter-studie evalueredes 14 drenge (i alderen 2-9 år) med familiær mandlig pubertas praecox, også kendt som testotoksikose, behandlet med Arimidex og bicalutamid i kombination. 
An open-label, non-comparative, multi-centre study evaluated 14 male patients (aged 2 to 9 years) with familial male-limited precocious puberty, also known as testotoxicosis, treated with combination of Arimidex and bicalutamide.
Tid til recidiv defineres som den første forekomst af loko-regionalt recidiv, kontralateral ny brystkræft, fjernt recidiv eller død på grund af brystkræft. 
Time to recurrence is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death due to breast cancer.
I et fertilitetsforsøg blev afvænnede hanrotter doseret i 10 uger med 50 eller 400 mg anastrozol per liter gennem drikkevandet. 
In a fertility study weanling male rats were dosed orally with 50 or 400 mg/l anastrozole via their drinking water for 10 weeks.
2-sidet 95 % CI 
2-sided 95% CI
Andenlinjebehandling hos postmenopausale kvinder med fremskreden brystkræft Arimidex blev undersøgt i to kontrollerede kliniske forsøg (studie 0004 og studie 0005) hos postmenopausale kvinder med fremskreden brystkræft, der havde sygdomsprogression efter tamoxifenbehandling for enten fremskreden eller tidlig brystkræft. 
Second-line therapy in postmenopausal women with advanced breast cancer Arimidex was studied in two controlled clinical trials (Study 0004 and Study 0005) in postmenopausal women with advanced breast cancer who had disease progression following tamoxifen therapy for either advanced or early breast cancer.
Yderligere information om Arimidex er tilgængelig på Lægemiddelstyrelsens hjemmeside. 
Detailed information on this medicine is available on the web site of {MA/Agency}
AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA Storbritannien 
AstraZeneca UK Ltd Silk Road Business Park Macclesfield Cheshire SK10 2NA United Kingdom
Hver filmovertrukken tablet indeholder 1 mg anastrozol. 
Each film-coated tablet contains 1 mg of anastrozole.
Humørsvingninger 
Mood disturbances
Tag ikke Arimidex - hvis du er overfølsom (allergisk) over for anastrozol eller et af de øvrige indholdsstoffer 
Do not take Arimidex - if you are allergic (hypersensitive) to anastrozole or any of the other ingredients of Arimidex (see section 6: Further information).
I et randomiseret, dobbeltblindet, multicenter-studie blev 52 drenge i puberteten (i alderen 11 til og med 16 år) med GHD behandlet i 12 til 36 måneder med Arimidex 1 mg/dag eller placebo i kombination med væksthormon. 
A randomised, double-blind, multi-centre study evaluated 52 pubertal boys (aged 11 to 16 years inclusive) with GHD treated for 12 to 36 months with Arimidex 1 mg/day or placebo in combination with growth hormone.
I et toårigt onkogenicitetsforsøg med rotter blev der kun set en stigning i forekomsten af hepatiske neoplasmer og uterine stromale polypper hos hundyr og tyroide adenomer hos handyr ved den høje dosis (25 mg/kg/dag). 
A two-year rat oncogenicity study resulted in an increase in incidence of hepatic neoplasms and uterine stromal polyps in females and thyroid adenomas in males at the high dose (25 mg/kg/day) only.
Søvnighed Karpaltunnelsyndrom* 
Somnolence Carpal Tunnel Syndrome*
[Se bilag I - Udfyldes nationalt] anastrozol 
[See Annex I - To be completed nationally] anastrozole
Arimidex er ikke blevet undersøgt hos brystkræftpatienter med moderat eller svært nedsat leverfunktion. 
Arimidex has not been investigated in breast cancer patients with moderate or severe hepatic impairment.
Arimidex sænker mængden af hormonet østrogen i din krop. 
Arimidex lowers the amount of the hormone called estrogen that is in your body.
Myokardieinfarkt 
Myocardial infarct
Førstelinjebehandling hos postmenopausale kvinder med fremskreden brystkræft To dobbeltblindede, kontrollerede kliniske studier (studie 1033IL/0030 og studie 1033IL/0027) blev udført for at vurdere effekten af Arimidex sammenlignet med tamoxifen som førstelinjebehandling af lokalt fremskreden eller metastatisk brystkræft hos postmenopausale kvinder, enten hormonreceptorpositiv eller med ukendt hormonreceptor-status. 
First-line therapy in postmenopausal women with advanced breast cancer Two double-blind, controlled clinical studies of similar design (Study 1033IL/0030 and Study 1033IL/0027) were conducted to assess the efficacy of Arimidex compared with tamoxifen as first-line therapy for hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer in postmenopausal women.
Det er usandsynligt, at Arimidex vil påvirke evnen til at føre motorkøretøjer, arbejde med værktøj eller betjene maskiner. 
Arimidex is not likely to affect your ability to drive or use any tools or machines.
Adjuverende behandling af tidlig invasiv brystkræft hos hormonreceptor-positive patienter 
Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patients
Tid til et vilkårligt recidiv Hazard ratio 
Time to distant recurrence Hazard ratio
0,70 til 1,00 
0.70 to 1.00
• Betændelse i huden, der kan vise sig ved røde pletter eller blærer. 
• Rare inflammation of your skin that may include red patches or blisters.
Adjuverende behandling af tidlig invasiv brystkræft hos hormonreceptor-positive patienter, som behandles med adjuverende tamoxifen 
Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patients being treated with adjuvant tamoxifen
Almene symptomer og reaktioner på administrationsstedet. 
General disorders and administration site conditions
• Patienter med overfølsomhed over for anastrozol eller over for et eller flere af hjælpestofferne, 
• Patients with known hypersensitivity to anastrozole or to any of the excipients as referenced in section 6.1.
Indgivelse af tamoxifen eller østrogenholdig behandling sammen med Arimidex bør undgås, da dette kan mindske dets farmakologiske virkning (se pkt. 
Co-administration of tamoxifen or estrogen-containing therapies with Arimidex should be avoided as this may diminish its pharmacological action (see section 4.5 and 5.1).
Diarré Opkastning 
Diarrhoea Vomiting
Arimidex er ikke blevet undersøgt hos brystkræftpatienter med svært nedsat nyrefunktion. 
Arimidex has not been investigated in breast cancer patients with severe renal impairment.
Antal hændelser (frekvens) Intent-to-treat-population 
Number of events (frequency) Intention-to-treat population Hormone receptor-positive tumour status
Hvis det sker for dig, skal du spørge din læge eller apoteket til råds. 
If this happens to you, ask your doctor or pharmacist for advice.
• Adjuverende behandling af hormonreceptor-positiv tidlig invasiv brystkræft hos postmenopausale kvinder, der har fået adjuverende tamoxifen i 2-3 år. 
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
0,19 til 1,13 
0.19 to 1.13
Forsøg 0006 var et randomiseret, dobbeltblindet, multicenter-studie med 82 drenge i puberteten (i alderen 11 til og med 18 år) med gynækomasti af over 12 måneders varighed behandlet med Arimidex 1 mg/dag eller placebo dagligt i op til 6 måneder. 
Trial 0006 was a randomised, double-blind, multi-centre study of 82 pubertal boys (aged 11-18 years inclusive) with gynaecomastia of greater than 12 months duration treated with Arimidex 1 mg/day or placebo daily for up to 6 months.
0,49 til 0,92 
0.49 to 0.92
Der er ingen data fra anvendelse af Arimidex under amning. 
There are no data on the use of Arimidex during lactation.
Dette lægemiddel indeholder lactose og bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form for arvelig lactasemangel (Lapp Lactase deficiency) eller glucosegalactose-malabsorption. 
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Plasmakoncentrationerne af anastrozol hos frivillige med levercirrose lå inden for det koncentrationsområde, som sås hos normale forsøgspersoner i andre forsøg. 
However, plasma anastrozole concentrations in the volunteers with hepatic cirrhosis were within the range of concentrations seen in normal subjects in other trials.
• For høje niveauer af kolesterol (fedt) i blodet. 
• Raised or high levels of a fatty substance known as cholesterol in your blood.
Der tilrådes, at der udvises forsigtighed hos patienter med moderat til svært nedsat leverfunktion (se pkt. 
Caution is advised in patients with moderate to severe hepatic impairment (see section 4.4).
0,31 til 0,88 
0.31 to 0.88
• Behandling af hormonreceptor-positiv fremskreden brystkræft hos postmenopausale kvinder. 
• Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.
Meget sjældne bivirkninger (påvirker færre end 1 person ud af 10.000) 
Very rare side effects (affect less than 1 person in 10,000 people)
Det skal du vide, før du begynder at tage Arimidex Sådan skal du tage Arimidex Bivirkninger 
What Arimidex is and what it is used for Before you take Arimidex How to take Arimidex Possible side effects
Enhver venøs tromboembolisk hændelse Dyb venetrombose, inklusive lungeemboli Iskæmiske, cerebrovaskulære hændelser Endometriecancer 
Any venous thromboembolic event Deep venous thromboembolic events including PE (pulmonary embolism)
0,85 til 1,12 
0.85 to 1.12
0,63 til 1,46 
0.63 to 1.46
- Øvrige indholdsstoffer: lactosemonohydrat, povidon, natriumstivelsesglycolat, 
- The other ingredients are: lactose monohydrate, povidone, sodium starch glycollate, magnesium stearate, hypromellose, macrogol 300, titanium dioxide.
Fortæl altid til lægen eller på apoteket, hvis du bruger anden medicin eller har brugt det for nylig. 
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Ledsmerter/stivhed 
Joint pain/stiffness
Vær ekstra forsigtig med at tage Arimidex 
Take special care with Arimidex
Hvis det er tilfældet for dig, skal du spørge din læge eller apoteket til råds. 
If this applies to you, ask your doctor or pharmacist for advice.
Der er ikke tegn på, at de farmakokinetiske parametre for anastrozol er tids- eller dosisafhængige. 
There is no evidence of time or dose-dependency of anastrozole pharmacokinetic parameters.
0,64 til 0,87 
0.64 to 0.87
0,80 til 1,07 
0.80 to 1.07
0,35 til 0,79 
0.35 to 0.79
Meget almindelige bivirkninger (påvirker flere end 1 ud af 10 personer) 
Very common side effects (affect more than 1 in 10 people)
0,70 til 0,90 
0.70 to 0.90
• Adjuverende behandling af hormonreceptor-positiv tidlig invasiv brystkræft hos postmenopausale kvinder. 
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.
Batchfrigivelsessteder 
Batch release sites
Plasmakoncentrationerne af anastrozol, observeret under langvarige behandlingsforsøg hos patienter med nedsat nyrefunktion, lå inden for det plasmakoncentrationsområde, der blev set hos patienter uden nedsat nyrefunktion. 
Plasma anastrozole concentrations observed during longterm efficacy trials in patients with renal impairment were within the range of plasma anastrozole concentrations seen in patients without renal impairment.
Arimidex er kontraindiceret under amning (se pkt. 
Arimidex is contraindicated during breast-feeding (see section 4.3).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukken tablet indeholder 1 mg anastrozol. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 1 mg anastrozole.
Hazard ratio 2-sidet 95 % CI 
Hazard ratio 2-sided 95% CI
6: Yderligere oplysninger). 
See leaflet for further information.
Meget almindelig Kløe 
Very common Asthenia
0,78 til 0,97 
0.78 to 0.97
0,83 til 1,14 
0.83 to 1.14
Hos patienter med svært nedsat nyrefunktion skal Arimidex administreres med forsigtighed (se pkt. 
In patients with severe renal impairment, administration of Arimidex should be performed with caution (see section 4.4 and 5.2).
0,83 til 1,06 
0.83 to 1.06
0,39 til 0,89 
0.39 to 0.89
Dosisjustering er ikke nødvendig hos patienter med let til moderat nedsat nyrefunktion. 
No dose change is recommended in patients with mild or moderate renal impairment.
0,73 til 0,94 
0.73 to 0.94
SÅDAN SKAL DU TAGE ARIMIDEX 
HOW TO TAKE ARIMIDEX
Virkning på knoglemineraltæthed 
Effect on bone mineral density
Sjældne bivirkninger (påvirker mellem 1 og 10 personer ud af 10.000) 
Rare side effects (affect 1 to 10 people in 10,000)
Ikke almindelig Stigning i gamma-GT og bilirubin 
Increases in gamma-GT and bilirubin Hepatitis Very common Rash Common
Arimidex og tilhørende navne (se bilag I) 1 mg filmovertrukne tabletter 
Arimidex and associated names (see Annex I) 1 mg film-coated tablets
0,74 til 0,99 
0.74 to 0.99
I et fase III-forsøg (Austrian Breast and Colorectal Cancer Study Group [ABCSG] 8) indgik 2.579 postmenopausale kvinder med hormonreceptor-positiv tidlig brystkræft, der var blevet opereret med eller uden strålebehandling og uden kemoterapi (se nedenfor). 
In a phase III trial (Austrian Breast and Colorectal Cancer Study Group [ABCSG] 8) conducted in 2,579 postmenopausal women with hormone receptor-positive early breast cancer who had received surgery with or without radiotherapy and no chemotherapy (see below), switching to Arimidex after 2 years adjuvant treatment with tamoxifen was statistically superior in disease-free survival when compared to remaining on tamoxifen, after a median follow-up of 24 months.
LÆGEMIDLETS NAVN Arimidex og tilhørende navne (se bilag I) 1 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT Arimidex and associated names (see Annex I) 1 mg film-coated tablets
Almindelige bivirkninger (påvirker mellem 1 og 10 personer ud af 100) 
Common side effects (affect 1 to 10 people in 100)
Lactosemonohydrat 
Myocardial ischaemia
Arimidex indeholder - Aktivt stof: anastrozol. 
- The active substance is anastrozole.
Samlet overlevelse Hazard ratio 2-sidet 95 % CI 
Overall survival Hazard ratio 2-sided 95% CI
Knoglesmerter 
Urticaria
Dosisjustering er ikke nødvendig hos patienter med let nedsat leverfunktion. 
No dose change is recommended in patients with mild hepatic disease.
Ikke almindelige bivirkninger (påvirker mellem 1 og 10 personer ud af 1.000) 
Uncommon side effects (affect 1 to 10 people in 1,000)
Sygdomsfri overlevelse Hazard ratio 2-sidet 95 % CI 
Disease-free survival Hazard ratio 2-sided 95% CI
Tid til fjernt recidiv Hazard ratio 2-sidet 95 % CI 
Time to any recurrence Hazard ratio 2-sided 95% CI
Træthed/asteni 
Fatigue/asthenia
0,30 til 0,76 
0.30 to 0.76
Kvalme og opkastning Frakturer 
Nausea and vomiting
se pkt. 
Bone pain
Arimidex og tilhørende navne (se bilag I) 1 mg filmovertrukne tabletter [Se bilag I - Udfyldes nationalt] 
NAME OF THE MEDICINAL PRODUCT Arimidex and associated names (see Annex I) 1 mg film-coated tablets [See Annex I - To be completed nationally]
Frakturer i hoften 
Hip fractures
Arimidex og tilhørende navne (se bilag I) 1 mg filmovertrukne tabletter [Se bilag I - Udfyldes nationalt] anastrozol 
NAME OF THE MEDICINAL PRODUCT Arimidex and associated names (see Annex I) 1 mg film-coated tablets [See Annex I - To be completed nationally] anastrozole
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE ARIMIDEX 
BEFORE YOU TAKE ARIMIDEX
Spørg lægen eller på apoteket, inden du tager Arimidex, hvis du er i tvivl. 
If you are not sure, talk to your doctor or pharmacist before taking Arimidex.
Dette kaldes ‘Schönlein-Henoch purpura'. 
Very rarely symptoms of joint, stomach, and kidney pain may occur; this is known as ‘Henoch-Schönlein purpura'.
• Mathed. 
• Bone pain.
Hedeture 
Excipients
Arimidex skal anvendes med forsigtighed hos patienter med moderat og svært nedsat leverfunktion (se pkt. 
Exposure to anastrozole can be increased in subjects with hepatic impairment (see section 5.2); administration of Arimidex in patients with moderate and severe hepatic impairment should be performed with caution (see section 4.2).
Eksponering for anastrozol er ikke øget hos forsøgspersoner med svært nedsat nyrefunktion (GRF <30 ml/min, se pkt. 
Exposure to anastrozole is not increased in subjects with severe renal impairment (GRF<30ml/min, see section 5.2); in patients with severe renal impairment, administration of Arimidex should be performed with caution (see section 4.2).
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt her. 
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Hold ikke op med at tage dine tabletter, medmindre din læge beder dig om det. Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om. 
You should check with your doctor or pharmacist if you are not sure.
• Knoglesmerter. 
• Hot flushes.
Dette tager normalt adskillige sekunder. 
This normally takes several seconds.
Det meste af kønsforskellen skyldes forskelle i kropsvægt. 
Most of the gender difference is accounted for by differences in body weight.
c p-værdi for PGI-C er nominel. 
c p-value for PGI-C is nominal.
Gennemgang af behandling anbefales, hvis sådanne symptomer udvikler sig. 
Review of treatment is recommended if such symptoms develop.
Du kan udsætte dig selv og andre for risiko for alvorlig skade eller død. 
You could put yourself or others at risk of serious injury or death.
Din læge kan få brug for at gennemgå din behandling. 
Your doctor may need to review your treatments.
Daglige doser (median) 
Daily doses (median)
Tag en dyb, behagelig indånding, indtil dine lunger føles fyldte. 
Take in a deep, comfortable breath until your lungs feel full.
Andre bivirkninger du kan opleve, hvor hyppigheden er ukendt, indbefatter: 
Other side effects you may experience of which the frequency is not known include:
Klar til opbevaring 
Ready for storage
Tlf: +353 (0)1 231 4609 
Tel: +353 (0)1 231 4609
Sørg for, at dine hænder er rene og tørre. 
Make sure your hands are clean and dry.
Find en ren og tør overflade. 
Find a clean and dry surface.
Varighed af PD 
Duration PD
Resultaterne er vist i Tabel 2. 
Results are presented in Table 2.
- nye eller forøgede abnorme kropsbevægelser (dyskinesi), 
- new or increased abnormal body movements (dyskinesia);
Meget forbedret % (n) Forbedret % (n) Lidt forbedret % (n) Ikke forbedret % (n) p-værdi 
Much improved % (n) Improved % (n) Little improved % (n) Not improved % (n) p-value